CAIRE Diagnostics is focused on enabling asthma patients to live with confidence through better monitoring and control of their condition. The company was founded in 2011 as Spirosure, Inc. Since then, it has led innovation in asthma diagnostics with the introduction of the FenomPro monitor that uses the novel FeNO technology to easily and cost-effectively detect signs of inflammation to proactively manage asthma and avoid unpleasant and dangerous symptoms. This technology has become a recommended measurement by the recent Global Initiative for Asthma (GINA) guidelines.

In 2020, Spirosure was purchased by CAIRE, a global leader in respiratory products, creating CAIRE Diagnostics. Now even stronger, our company is investing in expanding access to FeNO testing to enable patients to control their asthma and live with peace-of-mind.